Stock listing
NASDAQ:KZIA Kazia Therapeutics Ltd Stock
Follow Kazia Therapeutics Ltd into a list and get an email when it puts out news.
Share price · NASDAQ:KZIA
$4.92 USD -0.57 (-10.4%)
Close on Nov 20, 2026
- Day range
- $4.50 – $5.48 USDNov 20, 2026
- Volume
- 731,926 sharesNov 20, 2026
- Market cap
- $56.22M USDAt the close on Nov 20, 2026 · price × 11.43M shares outstanding
- 52-week range
- $4.50 – $17.40 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.91M USDMedian day 226,313 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KZIA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.92 | -0.57 | -10.4% | $5.25 | $5.48 | $4.50 | 731,926 | |
| $5.49 | +0.18 | +3.4% | $5.25 | $5.75 | $5.25 | 226,313 | |
| $5.31 | -0.29 | -5.2% | $5.61 | $5.85 | $5.20 | 650,804 | |
| $5.60 | -1.02 | -15.4% | $6.68 | $6.69 | $5.36 | 1,408,948 | |
| $6.62 | -0.33 | -4.7% | $6.88 | $6.995 | $6.255 | 352,750 | |
| $6.95 | -0.48 | -6.5% | $7.50 | $7.65 | $6.81 | 166,345 | |
| $7.43 | +0.03 | +0.4% | $7.51 | $7.72 | $7.33 | 154,472 | |
| $7.40 | -0.01 | -0.1% | $7.41 | $7.812 | $7.32 | 130,854 | |
| $7.41 | +0.23 | +3.2% | $7.30 | $7.57 | $7.25 | 123,539 | |
| $7.18 | +0.18 | +2.6% | $7.01 | $7.40 | $6.89 | 155,355 | |
| $7.00 | -1.08 | -13.4% | $7.99 | $7.99 | $7.00 | 186,157 | |
| $8.08 | 0.00 | 0.0% | $8.27 | $8.54 | $7.74 | 238,418 | |
| $8.08 | +0.06 | +0.7% | $8.01 | $8.226 | $7.931 | 114,542 | |
| $8.02 | -0.48 | -5.6% | $8.63 | $8.75 | $7.804 | 156,039 | |
| $8.50 | -0.22 | -2.5% | $8.71 | $8.71 | $7.92 | 230,400 | |
| $8.72 | +0.39 | +4.7% | $9.10 | $9.10 | $8.35 | 220,800 | |
| $8.33 | +0.16 | +2.0% | $8.27 | $8.37 | $8.06 | 160,800 | |
| $8.17 | +0.30 | +3.8% | $8.03 | $8.54 | $7.81 | 231,900 | |
| $7.87 | +0.06 | +0.8% | $8.00 | $8.18 | $7.60 | 189,200 | |
| $7.81 | -0.26 | -3.2% | $7.98 | $8.06 | $7.48 | 52,700 | |
| $8.07 | -0.11 | -1.3% | $8.04 | $8.36 | $7.25 | 128,800 | |
| $8.18 | +0.30 | +3.8% | $8.11 | $8.38 | $8.04 | 166,100 | |
| $7.88 | +0.03 | +0.4% | $8.21 | $8.21 | $7.81 | 168,200 | |
| $7.85 | +0.60 | +8.3% | $7.42 | $7.93 | $7.31 | 245,200 | |
| $7.25 | -0.15 | -2.0% | $7.44 | $7.79 | $7.15 | 273,200 | |
| $7.40 | +0.61 | +9.0% | $6.80 | $7.59 | $6.80 | 385,700 | |
| $6.79 | -1.25 | -15.5% | $7.85 | $8.31 | $6.62 | 825,300 | |
| $8.04 | -0.77 | -8.7% | $8.77 | $8.94 | $8.00 | 273,800 | |
| $8.81 | -0.12 | -1.3% | $9.05 | $9.18 | $8.72 | 66,800 | |
| $8.93 | +0.11 | +1.2% | $8.89 | $9.08 | $8.75 | 123,400 | |
| $8.82 | -0.47 | -5.1% | $9.25 | $9.51 | $8.71 | 252,400 | |
| $9.29 | +0.03 | +0.3% | $9.20 | $9.53 | $9.14 | 133,500 | |
| $9.26 | -0.09 | -1.0% | $9.53 | $9.65 | $9.16 | 129,900 | |
| $9.35 | +0.08 | +0.9% | $9.31 | $9.54 | $9.12 | 240,600 | |
| $9.27 | -0.20 | -2.1% | $9.59 | $9.74 | $9.12 | 128,700 | |
| $9.47 | -0.13 | -1.4% | $9.56 | $9.69 | $9.37 | 132,200 | |
| $9.60 | -0.15 | -1.5% | $9.90 | $9.90 | $9.46 | 188,100 | |
| $9.75 | +0.15 | +1.6% | $9.72 | $9.84 | $9.43 | 176,400 | |
| $9.60 | +0.03 | +0.3% | $9.44 | $10.26 | $9.33 | 285,500 | |
| $9.57 | -0.21 | -2.1% | $9.77 | $9.99 | $9.42 | 244,300 | |
| $9.78 | +0.18 | +1.9% | $9.50 | $9.99 | $9.01 | 561,000 | |
| $9.60 | -1.32 | -12.1% | $10.95 | $10.95 | $9.23 | 526,500 | |
| $10.92 | +0.27 | +2.5% | $10.80 | $11.25 | $10.71 | 321,100 | |
| $10.65 | +0.26 | +2.5% | $10.53 | $10.79 | $10.19 | 193,500 | |
| $10.39 | -0.47 | -4.3% | $10.89 | $11.00 | $10.38 | 169,900 | |
| $10.86 | +0.66 | +6.5% | $10.52 | $10.90 | $10.16 | 446,800 | |
| $10.20 | -0.16 | -1.5% | $10.50 | $10.97 | $10.15 | 353,800 | |
| $10.36 | -0.80 | -7.2% | $11.11 | $11.11 | $10.21 | 495,700 | |
| $11.16 | -0.03 | -0.3% | $11.12 | $11.64 | $11.12 | 153,200 | |
| $11.19 | +0.18 | +1.6% | $11.10 | $11.43 | $10.83 | 340,700 | |
| $11.01 | -0.87 | -7.3% | $11.75 | $11.75 | $10.83 | 374,300 | |
| $11.88 | -0.13 | -1.1% | $12.50 | $12.75 | $11.76 | 238,000 | |
| $12.01 | -0.30 | -2.4% | $12.29 | $12.47 | $11.95 | 158,700 | |
| $12.31 | +0.15 | +1.2% | $12.00 | $12.62 | $11.77 | 414,400 | |
| $12.16 | -0.45 | -3.6% | $12.62 | $12.99 | $12.04 | 413,500 | |
| $12.61 | -0.02 | -0.2% | $12.66 | $13.13 | $12.05 | 359,100 | |
| $12.63 | -1.14 | -8.3% | $13.69 | $13.69 | $12.27 | 612,100 | |
| $13.77 | +0.19 | +1.4% | $13.70 | $14.42 | $13.00 | 377,900 | |
| $13.58 | -3.32 | -19.6% | $15.48 | $15.50 | $13.30 | 1,179,300 | |
| $16.90 | +2.30 | +15.8% | $14.67 | $17.18 | $14.67 | 985,900 | |
| $14.60 | +0.81 | +5.9% | $13.79 | $14.79 | $13.62 | 100,700 | |
| $13.79 | +0.59 | +4.5% | $13.25 | $13.98 | $13.25 | 92,900 | |
| $13.20 | -0.21 | -1.6% | $13.36 | $13.42 | $13.00 | 61,800 | |
| $13.41 | -0.26 | -1.9% | $13.67 | $13.96 | $13.06 | 149,000 | |
| $13.67 | -0.40 | -2.8% | $13.96 | $13.97 | $13.44 | 99,600 |
Splits
5 splits since 2012 · NASDAQ:KZIA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-5 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-4 | Consolidation | |
| 161-for-53 | Split | |
| 1-for-5 | Consolidation |
- Ticker
- NASDAQ:KZIA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026
Latest deck · Sep 1, 2026
Corporate Update (September 2026)
Corporate update · 21 slides
Latest news
Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026
Nov 19, 2026
Closed $4.92 (-10.4%) on Nov 20, 2026
Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader
Nov 12, 2026
Closed $6.95 (-6.5%) on Nov 12, 2026
Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards
Nov 5, 2026
Closed $7.00 (-13.4%) on Nov 5, 2026
Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
Nov 2, 2026
Closed $8.02 (-5.6%) on Nov 2, 2026
Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference
Oct 29, 2026
Closed $8.72 (+4.7%) on Oct 29, 2026
Kazia Therapeutics Ltd on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 5 in the last 12 months · 5 in all · newest Nov 19, 2026 · oldest 2026
- Decks
- 64 decks · latest Sep 1, 2026
Valuation
EV/sales 373× against a median of 8.5×: the highest of 7 Biotechnology companies shown. Statements: Year to Jun 30, 2025 · balance Dec 31, 2025 · price Nov 20, 2026
- Enterprise value
- $10.36M USD
- P/E
- Loss
- EV/sales
- 373×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.8×
- Gross margin
- 100.0%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 2.31
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Kazia Therapeutics Ltd · NASDAQ:KZIA | US$56.22M | US$10.36M | n/a | 373× | n/a | 1.8× | n/a | 0.0× | 2.31 |
| iNtRON Biotechnology, Inc. · KRX:048530 | US$57.38M | US$31.38M | n/a | 5.8× | n/a | 1.2× | −142.6% | 0.0× | n/a |
| HeXun Biosciences Co Ltd · TPEX:6986 | US$57.20M | US$32.05M | 16.2× | 3.4× | 6.5× | 1.8× | 37.7% | 0.0× | n/a |
| Tenax Therapeutics, Inc. · NASDAQ:TENX | US$56.92M | −US$56.78M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.35 |
| OKYO Pharma Limited · NASDAQ:OKYO | US$56.15M | US$35.56M | n/a | n/a | n/a | 4.5× | n/a | 0.0× | 1.02 |
| Gwo Xi Stem Cell Applied Technology Co., Ltd. · TPEX:6704 | US$55.77M | US$51.65M | n/a | 9.1× | n/a | 2.5× | −43.0% | 0.3× | n/a |
| EyeGene, Inc. · KRX:185490 | US$55.57M | US$26.66M | n/a | 8.0× | n/a | 1.5× | −391.5% | 0.0× | n/a |
| Cognition Therapeutics, Inc. · NASDAQ:CGTX | US$55.37M | US$25.10M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 2.28 |
| AB Science SA · EURONEXT:AB | US$55.19M | US$50.54M | n/a | 39.2× | n/a | n/a | −132.6% | n/a | n/a |
| Azora Therapeutics, Inc. · NASDAQ:AZR | US$55.00M | US$33.00M | n/a | n/a | n/a | n/a | n/a | n/a | 1.00 |
| Island Pharmaceuticals Ltd · ASX:ILA | US$54.84M | US$46.32M | n/a | 248× | n/a | 6.2× | n/a | 0.0× | n/a |
| Median of the others | US$55.67M | US$32.53M | 16.2× | 8.5× | 6.5× | 1.8× | −132.6% | 0.0× | 1.19 |
Forecasts
6 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 9, 2026. Not 6ix's view and not investment advice.
- Price target
- 28.72 USD · Analysts' mean
- EPS, year to Jun 2026
- -0.011 · 3 analysts
- Revenue, year to Jun 2026
- 1.09M · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| John E. Friend | Chief Executive Officer |
| James Levine | Chief Financial Officer |
| Elissa Hansen | Company Secretary |
| Jeffrey J. Kraws | Head of Corporate Strategy & Development |
| Sudha Rao | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Robert Apple | Chairman |
| Ebru Davidson | Non-Executive Director |
| Steven Coffey | Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 6, 2026 | +5.9% |
| Q1 2026 | Nov 7, 2025 | −1.5% |
| Quarter to Mar 31, 2025 | Jun 10, 2025 | +80.0% |
| Q1 2025 | Nov 15, 2024 | −3.6% |
| Q3 2021 | Jun 30, 2021 | +1.3% |
| Q2 2021 | Mar 31, 2021 | +3.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (September 2026) | Corporate update | 21 slides | Sep 1, 2026 |
| Investor Presentation (August 2026) | Investor deck | 39 slides | Aug 27, 2026 |
| Investor Presentation (April 2026) | Investor deck | 59 slides | Apr 27, 2026 |
| Investor Presentation (April 2026) | Investor deck | 59 slides | April 2026 |
| Investor Presentation (March 2026) | Investor deck | 55 slides | Mar 31, 2026 |
| Shareholder Meeting (March 2026) | Shareholder meeting | 14 slides | Mar 26, 2026 |
| Investor Presentation (August 2025) | Investor deck | 40 slides | August 2025 |
| Investor Presentation (February 2025) | Investor deck | 43 slides | Feb 3, 2025 |
| Investor Presentation (January 2025) | Investor deck | 43 slides | January 2025 |
| Investor Presentation (November 2024) | Investor deck | 37 slides | November 2024 |
Show 50 decks
This page holds 50 of 64 decks. Open Decks
Financials
Annual, in AUD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.0K | 2.31M | 0 | 0 | 15.2M | 988.1K | 1.56K | 119.0K | 249.0K | 406.0K |
| Cost of revenue | 0 | 0 | 0 | 0 | ||||||
| Gross profit | 42.0K | 2.31M | 555 | 10.0K | 15.2M | 988.1K | 1.56K | 13.1K | 8.79M | 4.07M |
| Research and development | 7.33M | 17.4M | 15.6M | 20.2M | 14.5M | 9.49M | 6.47M | 9.77M | 11.1M | 9.89M |
| Selling, general and administrative | 8.72M | 13.6M | 8.58M | 5.11M | 7.02M | 3.69M | 3.79M | 5.60M | 8.53M | 5.76M |
| Operating income | -14.2M | -28.5M | -24.1M | -25.4M | -6.38M | -12.2M | -8.38M | -12.5M | -10.9M | -12.8M |
| Depreciation and amortization | 934.0K | 1.87M | 1.87M | 1.87M | 1.26M | 1.08M | 1.08M | 1.55M | 1.42M | 643.0K |
| EBITDA | -13.3M | -26.6M | -22.3M | -23.5M | -5.11M | -11.1M | -7.30M | -10.9M | -9.43M | -12.1M |
| Interest expense | 2.09K | 5.10M | 240.0K | 2.19M | 0 | 1.00K | 0 | |||
| Income before tax | -22.4M | -27.0M | -20.7M | -25.4M | -8.90M | -12.8M | -10.6M | -6.34M | -10.9M | -12.2M |
| Income tax | -1.75M | -271.0K | -271.0K | -368.0K | -484.0K | -298.0K | -298.0K | -305.0K | -199.0K | 2.77M |
| Net income | -20.7M | -26.8M | -20.5M | -25.0M | -8.42M | -12.5M | -10.3M | -6.04M | -10.7M | -12.1M |
| Earnings per share, basic | -0.04 | -0.10 | -0.11 | -0.19 | -0.07 | -0.17 | -17.86 | -12.48 | -2.28 | -2.82 |
| Earnings per share, diluted | -0.04 | -0.10 | -0.11 | -0.19 | -0.07 | -0.17 | -17.86 | -12.48 | -2.28 | -2.82 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 4.34M | 1.66M | 5.24M | 7.36M | 27.6M | 8.76M | 5.43M | 5.96M | 14.5M | 33.5M |
| Short-term investments | 0 | 0 | 0 | 0 | ||||||
| Receivables | 97.9K | 3.90M | 3.90M | 91.0K | 84.0K | 1.35M | 1.71M | 2.54M | 4.26M | 91.0K |
| Inventory | -3.79M | -84.0K | 1 | -1.55M | 0 | 1 | 434.0K | |||
| Current assets | 4.93M | 6.14M | 10.8M | 9.45M | 29.4M | 10.7M | 7.51M | 9.26M | 19.5M | 34.1M |
| Property, plant and equipment | 0 | 1.00K | 490.0K | 592.0K | ||||||
| Goodwill | 0 | 0 | 0 | 0 | ||||||
| Total assets | 6.06M | 21.6M | 28.1M | 35.9M | 58.1M | 23.1M | 21.2M | 28.2M | 35.9M | 35.5M |
| Accounts payable | 10.1M | 15.1M | 4.33M | 3.76M | 4.93M | 3.49M | 1.76M | 2.07M | 1.87M | 512.0K |
| Current liabilities | 14.1M | 25.8M | 7.57M | 6.73M | 8.33M | 5.07M | 1.90M | 3.89M | 5.38M | 1.43M |
| Long-term debt | 0 | 0 | 0 | 0 | ||||||
| Total debt | 396.0K | 634.0K | 1.80M | 1.84M | 0 | 84.0K | 10.0K | 10.0K | ||
| Total liabilities | 14.4M | 31.6M | 16.0M | 17.6M | 20.2M | 8.94M | 6.98M | 8.93M | 10.6M | 1.59M |
| Shareholders' equity | -8.30M | -10.0M | 12.1M | 18.3M | 37.9M | 14.1M | 14.2M | 19.2M | 25.3M | 33.9M |
| Shares outstanding | 1.10M | 479.6K | 368.6K | 265.0K | 235.4K | 152.5K | 120.0K | 101.0K | 97.6K | 89.2K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -13.3M | -9.58M | -15.2M | -22.8M | -9.11M | -8.81M | -6.71M | -8.66M | -11.4M | -12.0M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -12.0K | -522.0K |
| Free cash flow | -13.3M | -9.58M | -15.2M | -22.8M | -9.11M | -8.81M | -6.71M | -8.66M | -11.4M | -12.5M |
| Cash from investing | 0 | 0 | -2.37M | -2.36M | -2.36M | 2.36M | 150.0K | -7.12M | -522.0K | |
| Cash from financing | 16.0M | 5.99M | 13.0M | 3.73M | 28.1M | 12.1M | 3.82M | 3.82M | -18.0K | 782.0K |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Share buybacks | 3.82M | 0 | 0 | 852.9K | ||||||
| Change in cash | 2.70M | -3.60M | -2.18M | -21.4M | 19.0M | 3.33M | -539.0K | -8.51M | -18.6M | -11.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 19, 2026 | Current report | SEC |
| 20-F · Annual report | Nov 17, 2026 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| NT 20-F | Nov 2, 2026 | Explanation request | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 2, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Sep 22, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Sep 22, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Sep 22, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Sep 22, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Sep 22, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 424B3 · Prospectus | Sep 18, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Sep 18, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Sep 18, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Sep 18, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Sep 18, 2026 | Current report | SEC |
| 424B3 · Prospectus | Sep 1, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Sep 1, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Sep 1, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Sep 1, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Sep 1, 2026 | Current report | SEC |
| 424B3 · Prospectus | Aug 31, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Aug 31, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Aug 31, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Aug 31, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Aug 31, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 31, 2026 | Current report | SEC |
| 424B5 · Prospectus | Aug 31, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Aug 28, 2026 | Current report | SEC |
| 424B5 · Prospectus | Aug 28, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Aug 27, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Aug 27, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Aug 27, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Aug 27, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Aug 27, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Aug 27, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 19, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jul 28, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Jul 28, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Jul 28, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Jul 28, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jul 28, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 15, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 3, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 2, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Jun 2, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Jun 2, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Jun 2, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jun 2, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 27, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | May 26, 2026 | Offer document | SEC |
| 424B3 · Prospectus | May 26, 2026 | Offer document | SEC |
| 424B3 · Prospectus | May 26, 2026 | Offer document | SEC |
| 424B3 · Prospectus | May 26, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | May 26, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | May 19, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Apr 27, 2026 | Current report | SEC |
| 424B3 · Prospectus | Apr 15, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Apr 15, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Apr 15, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Apr 15, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Apr 15, 2026 | Current report | SEC |
| 424B3 · Prospectus | Apr 13, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Apr 13, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Apr 13, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Apr 13, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Apr 13, 2026 | Current report | SEC |
| 3/A · Initial statement of ownership, amended | Apr 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
| 424B3 · Prospectus | Mar 31, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Mar 31, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Mar 31, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Mar 31, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Mar 31, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 31, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 30, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Mar 30, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Mar 30, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 26, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 25, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Mar 19, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Mar 19, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Mar 19, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Mar 19, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Mar 19, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| F-3 · Registration statement | Mar 17, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 20, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jan 27, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Jan 27, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Jan 27, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Jan 27, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jan 27, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 23, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Dec 29, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Dec 29, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Dec 23, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 23, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 23, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 23, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 23, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Dec 23, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 22, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 22, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Dec 19, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Dec 19, 2025 | Offer document | SEC |
| F-1/A · Registration statement, amended | Dec 19, 2025 | Offer document | SEC |
| F-1 · Registration statement | Dec 19, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Dec 19, 2025 | Current report | SEC |
| D | Dec 18, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Dec 10, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 5, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 2, 2025 | Current report | SEC |
| 424B3 · Prospectus | Nov 18, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 18, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Nov 18, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Nov 18, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 20-F · Annual report | Nov 7, 2025 | Annual report | SEC |
| NT 20-F | Oct 31, 2025 | Explanation request | SEC |
| 424B3 · Prospectus | Oct 7, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 7, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 7, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Oct 7, 2025 | Current report | SEC |
| 424B3 · Prospectus | Oct 2, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 2, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Oct 2, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Oct 2, 2025 | Current report | SEC |
| F-1 · Registration statement | Sep 30, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Sep 12, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Sep 11, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Sep 11, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Sep 11, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Sep 11, 2025 | Current report | SEC |
| D | Aug 14, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 5, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Aug 1, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Aug 1, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Aug 1, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Aug 1, 2025 | Current report | SEC |
| 424B3 · Prospectus | Jul 25, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jul 25, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jul 25, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jul 25, 2025 | Current report | SEC |
| 424B5 · Prospectus | Jul 25, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jul 9, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jul 9, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jul 9, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jul 9, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 12, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Jun 11, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jun 11, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jun 11, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jun 11, 2025 | Current report | SEC |
| 424B3 · Prospectus | Jun 10, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jun 10, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jun 10, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jun 10, 2025 | Current report | SEC |
| 424B3 · Prospectus | Jun 5, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jun 5, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Jun 5, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jun 5, 2025 | Current report | SEC |
| 424B3 · Prospectus | May 28, 2025 | Offer document | SEC |
| 424B3 · Prospectus | May 28, 2025 | Offer document | SEC |
| 424B3 · Prospectus | May 28, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | May 28, 2025 | Current report | SEC |
| 424B3 · Prospectus | May 15, 2025 | Offer document | SEC |
| 424B3 · Prospectus | May 15, 2025 | Offer document | SEC |
| 424B3 · Prospectus | May 15, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | May 15, 2025 | Current report | SEC |
| 424B3 · Prospectus | Apr 15, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Apr 15, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Apr 15, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Apr 15, 2025 | Current report | SEC |
| 424B3 · Prospectus | Mar 31, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Mar 31, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Mar 31, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Mar 31, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 19, 2025 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Mar 13, 2025 | Current report | SEC |
| 424B3 · Prospectus | Feb 21, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 20, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 20, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Feb 20, 2025 | Current report | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Kazia Therapeutics Ltd’s releases
- Common shares
- 11,426,899
- Fully diluted
- 11,426,899
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 11,426,899 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 11,426,899 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| John E Friend II Other companies: Cellectar Biosciences, Inc. (Chief Medical Officer · Apr 17, 2017 – Mar 4, 2021 · Past) | Chief Executive Officer · Since at least Jan 8, 2026 |
| Robert Apple Other companies: Antares Pharma Inc (President and CEO, Director · Feb 9, 2006 – May 24, 2022 · Past) | Chairman · Since at least Jan 8, 2026 |
| Ebru Davidson | Non-Executive Director · Since at least Jan 8, 2026 |
| Elissa Hansen | Company Secretary · Since at least Nov 5, 2026 |
| James Levine | Chief Financial Officer · Since at least Nov 5, 2026 |
| Jeffrey Bonacorda | VP, Finance and Controller · Since at least Jan 8, 2026 |
| Jeffrey J. Kraws | Head of Corporate Strategy & Development · Since at least Oct 29, 2026 |
| Jeremy Simpson | Program Director · Since at least Mar 18, 2026 |
| John E. Friend | Chief Executive Officer · Since at least Oct 29, 2026 |
| Steven Coffey | Non-Executive Director · Since at least Nov 4, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Sudha Rao | Chief Scientific Officer · Since at least Apr 13, 2026 |
Log in to ask 6ix AI your own questions about Kazia Therapeutics Ltd.